A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis.

Van Der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR
Epidemiol Infect. 2015 143 (5): 960-5

PMID: 25420688 · PMCID: PMC4352378 · DOI:10.1017/S0950268814003136

SUMMARY Fluoroquinolone use before tuberculosis (TB) diagnosis delays the time to diagnosis and treatment, and increases the risk of fluoroquinolone-resistant TB and death. Ascertainment of fluoroquinolone exposure could identify such high-risk patients. We compared four methods of ascertaining fluoroquinolone exposure in the 6 months prior to TB diagnosis in culture-confirmed TB patients in Tennessee from January 2007 to December 2009. The four methods included a simple questionnaire administered to all TB suspects by health department personnel (FQ-Form), an in-home interview conducted by research staff, outpatient and inpatient medical record review, and TennCare pharmacy database review. Of 177 TB patients included, 72 (41%) received fluoroquinolones during the 6 months before TB diagnosis. Fluoroquinolone exposure determined by review of inpatient and outpatient medical records was considered the gold standard for comparison. The FQ-Form had 61% [95% confidence interval (CI) 48-73] sensitivity and 93% (95% CI 85-98) specificity (agreement 79%, kappa = 0.56) while the in-home interview had 28% (95% CI 18-40) sensitivity and 99% (94-100%) specificity (agreement 68%, kappa = 0.29). A simple questionnaire administered by health department personnel identified fluoroquinolone exposure before TB diagnosis with moderate reliability.

MeSH Terms (18)

Adult Anti-Bacterial Agents Databases, Factual Delayed Diagnosis Drug Resistance, Bacterial Female Fluoroquinolones Humans Interviews as Topic Male Medical History Taking Medical Records Middle Aged Pharmacies Surveys and Questionnaires Tennessee Tuberculosis Tuberculosis, Pulmonary

Connections (1)

This publication is referenced by other Labnodes entities: